Page last updated: 2024-12-06

alclofenac

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

alclofenac: was heading 1975-94 (was see under PHENYLACETATES 1975-90); use PHENYLACETATES to search ALCLOFENAC 1975-94; an anti-inflammatory agent used in the treatment of rheumatoid arthritis; acts also as an analgesic and an antipyretic [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

alclofenac : An aromatic ether in which the ether oxygen links an allyl group to the 4-position of (3-chlorophenyl)acetic acid.A non-steroidal anti-inflammatory drug, it was withdrawn from the UK market in 1979 due to concerns with its association with vasculitis and rash. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID30951
CHEMBL ID94081
CHEBI ID31183
SCHEMBL ID25703
MeSH IDM0224756

Synonyms (76)

Synonym
4-allyloxy-3-chlorophenylacetic acid
CHEMBL94081
chebi:31183 ,
alclofenac
benzeneacetic acid, 3-chloro-4-(2-propenyloxy)-
epinal
[3-chloro-4-(prop-2-en-1-yloxy)phenyl]acetic acid
einecs 244-795-4
my 101
alclofenaco [inn-spanish]
alclophenac
zumaril
neoston
alclofenacum [inn-latin]
marvan forte
prinalgin
mervan
3-chlor-4-allyloxy-phenylacetic acid
acetic acid, 4-allyloxy-3-chlorophenyl-
allopydin
neosten
(4-allyloxy-3-chlorphenyl)essigsaeure
reufenac
w 7320
[4-(allyloxy)-3-chlorophenyl]acetic acid
(4-(allyloxy)-3-chlorophenyl)acetic acid
desinflam
kyselina 4-allyloxy-3-chlorfenyloctova [czech]
medifenac
3-chloro-4-(2-propenyloxy)benzeneacetic acid
brn 2116510
NCGC00159507-03
NCGC00159507-02
alclofenac (jan/usp/inn)
D01252
mervan (tn)
34C ,
22131-79-9
FT-0661474
2-(3-chloro-4-prop-2-enoxyphenyl)acetic acid
cas-22131-79-9
dtxsid4020038 ,
tox21_111726
dtxcid9038
AKOS016014445
alclofenac [usan:inn:ban:jan]
alclofenaco
kyselina 4-allyloxy-3-chlorfenyloctova
m9cp5h21n8 ,
alclofenacum
unii-m9cp5h21n8
3-chloro-4-(2-propen-1-yloxy)benzeneacetic acid
[3-chloro-4-(allyloxy)phenyl]acetic acid
(4-allyloxy-3-chloro-phenyl)-acetic acid
EPITOPE ID:180854
W7320 ,
benzeneacetic acid, 3-chloro-4-(2-propen-1-yloxy)-
alclofenac [jan]
alclofenac [mart.]
alclofenac [who-dd]
alclofenac [inn]
alclofenac [usan]
my-101
alclofenac [mi]
W-7320 ,
SCHEMBL25703
4-allyloxy-3-chloro-phenylacetic acid
acetic acid, [4-(allyloxy)-3-chlorophenyl]-
2-(4-(allyloxy)-3-chlorophenyl)acetic acid
SR-01000945014-1
sr-01000945014
J-014540
DB13167
Q965999
EN300-9544389
2-[3-chloro-4-(prop-2-en-1-yloxy)phenyl]acetic acid

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011
)
0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
non-steroidal anti-inflammatory drugAn anti-inflammatory drug that is not a steroid. In addition to anti-inflammatory actions, non-steroidal anti-inflammatory drugs have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins.
non-narcotic analgesicA drug that has principally analgesic, antipyretic and anti-inflammatory actions. Non-narcotic analgesics do not bind to opioid receptors.
drug allergenAny drug which causes the onset of an allergic reaction.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
monocarboxylic acidAn oxoacid containing a single carboxy group.
monochlorobenzenesAny member of the class of chlorobenzenes containing a mono- or poly-substituted benzene ring in which only one substituent is chlorine.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AR proteinHomo sapiens (human)Potency26.60320.000221.22318,912.5098AID743040
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency2.68320.000214.376460.0339AID720691
estrogen nuclear receptor alphaHomo sapiens (human)Potency6.48350.000229.305416,493.5996AID743069; AID743075; AID743077; AID743078; AID743079
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency23.46430.001019.414170.9645AID743094; AID743140
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency19.95260.251215.843239.8107AID504327
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (10)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID384955Intrinsic aqueous solubility at pH 10 by shake-flask method2008Journal of medicinal chemistry, May-22, Volume: 51, Issue:10
Molecular characteristics for solid-state limited solubility.
AID625293Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in LTKB-BD2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625276FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of most concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID227700Anticonvulsant activity2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Topological virtual screening: a way to find new anticonvulsant drugs from chemical diversity.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (10.00)18.2507
2000's3 (30.00)29.6817
2010's5 (50.00)24.3611
2020's1 (10.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 33.62

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index33.62 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.97 (4.65)
Search Engine Demand Index42.09 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (33.62)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (10.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (90.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]